Biotechnology

Aditxt

Aditxt released FY2025 Q3 earnings on November 18 (EST), actual revenue USD 748, actual EPS USD -548.7813

Aditxt released FY2025 9 Months Earnings on November 18 (EST), actual revenue USD 2.77 K, actual EPS USD -938.9533

Aditxt released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 2.022 K, actual EPS USD -1.042 K

Aditxt released FY2025 Q2 earnings on August 14, 2025 (EST) with actual revenue of USD 1.004 K and EPS of USD -390.1719

Aditxt Inc. Collaborates with Crypto.com to Establish Crypto Accounts and List ADTX Stock

Aditxt Launches Bitcoin Strategy Plan 'bitXbio'

ADiTx Inc. CEO Discusses Company Potential and Growth Strategy

Aditxt Updates S-1 Filing With Digital Asset Financial Strategy

Aditxt Terminates Agreement with Appili Therapeutics

Aditxt released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 1.018 K, actual EPS USD 0

Aditxt Subsidiary Receives IRB Approval to Begin Clinical Study

Adimune Announces Positive Research Results for ADI-100, Plans Regulatory Submission

Aditxt Plans to Acquire Biotechnology Company Appili Therapeutics Focused on Infectious Diseases

Aditxt released FY2024 Annual Earnings on March 31 (EST), actual revenue USD 133.99 K (forecast USD 1.475 M), actual EPS USD 0

Aditxt released FY2024 Q4 earnings on March 31 (EST), actual revenue USD 3.175 K (forecast USD 425 K), actual EPS USD 0

Aditxt's subsidiary Pearsanta acquires a $1 million patent for compound omics technology aimed at early cancer detection

Biotechnology Company Aditxt Acquires Appili Therapeutics, Stock Price Rises 122%

Aditxt released FY2024 Q3 earnings on November 18 (EST), actual revenue 6.854 K USD (forecast 375 K USD), actual EPS 0 USD

Aditxt released FY2024 9 Months Earnings on November 18 (EST), with actual revenue of 130.81 K USD and EPS of 0 USD

ADITXT announces agreement with FDA

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Inspirato

Mega Fortune

Globavend

Andersen

Medline Inc.

ADMA生物制藥

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制藥

OpGen

福泰制藥

再生元制藥

Argenx

阿里拉姆制藥

百濟神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap